Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

The Company's cardiovascular medicine clinical trial program includes ONTARGET, PRoFESS, TRANSCEND and other studies involving more than 75,000 patients in more than 40 countries. These studies were designed to evaluate ways to reduce the risk of damaging events in the heart, brain and other organs due to cardiovascular disease and to uncover new treatment strategies that improve patient outcomes and care.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com .

About Micardis(R) (telmisartan)

Telmisartan is marketed in the United States by Boehringer Ingelheim as MICARDIS(R) tablets. MICARDIS is indicated for the treatment of hypertension.

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS tablets should be discontinued as soon as possible (see WARNINGS,
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:7/22/2014)... Bar, CA (PRWEB) July 22, 2014 ... leading provider of enterprise Time and Attendance / ... in Iowa, a NOVAtime 3000 customer since 2007, ... self-hosted, licensed version of NOVAtime’s state-of-the-art, web-based time ... Lutheran Services in Iowa (LSI) is a human ...
(Date:7/22/2014)... Orem, UT (PRWEB) July 22, 2014 Most people ... first is a weak appetite and the second is a fast ... CB-1 Weight Gainer provides ways to help fight these ... lack of appetite. There are people out there who just can’t ... take bites and then they are full. The cause of this ...
(Date:7/21/2014)... designed to target and kill cancer cells could boost ... and help avoid amputation, a new study reports. , ... the effectiveness of a genetically engineered version of the ... use of the virus alongside isolated limb perfusion chemotherapy ... arm or leg as an alternative to amputation ...
(Date:7/21/2014)... July 22, 2014 iFitDress.com, a famous ... women, has announced its exclusive collection of 2014 ... a promotion for its brand new gowns. , iFitDress.com ... the current market. Its sales boomed in the recent ... products, but also because of the amicable services offered ...
(Date:7/21/2014)... July 21, 2014 The League of ... 1199SEIU United Healthcare Workers East (“1199SEIU”) today announced a ... issues facing healthcare providers and their employees. , ... require ratification by League and 1199SEIU members, employee wages ... addition, all existing worker benefits, including healthcare coverage with ...
Breaking Medicine News(10 mins):Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 3
... 11 (HealthDay News) -- Low oxygen supply (hypoxia) increases the ... a severe traumatic brain injury (TBI), a new study finds. ... with TBI, most of whom had bleeding within the brain ... fared poorly, suffering severe disability, dying or being in a ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... demonstrated that cryoplasty post-dilitation compared to conventional balloon ... the risk of in-stent restenosis (ISR). Results from ... the 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...
... FRIDAY, Nov. 11 (HealthDay News) -- Repeated bouts of ... pain and infertility, a new study says. Pelvic inflammatory ... is marked by inflammation of the reproductive organs. The condition ... year and one in 10 of them becomes infertile, according ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... de novo coronary artery lesions showed a significantly ... to paclitaxel-eluting stents with permanent polymers. ... at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... the past 100 years, the Haber-Bosch process has been used ... the manufacture of fertilizer. Despite the longstanding reliability of the ... works. But now a team of chemists, led by Patrick ... how the ammonia is formed. Their findings are published in ...
... FRIDAY, Nov. 11 (HealthDay News) -- Age-related declines in ... to a new study. "The more income and ... be," co-author Virginia Richardson, a professor of social work ... release. The researchers analyzed data from roughly 6,500 ...
Cached Medicine News:Health News:Results of the COBRA trial reported at TCT 2011 2Health News:STD Complication May Double Infertility Risk 2Health News:Results of the NEXT clinical trial Reported at TCT 2011 2Health News:Researchers gain insight into 100-year-old Haber-Bbosch process 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: